易明医药
(002826)
| 流通市值：34.24亿 | | | 总市值：35.68亿 |
| 流通股本：1.83亿 | | | 总股本：1.91亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 182,577,229.06 | 636,272,038.57 | 488,983,972.66 | 311,445,583.3 |
| 营业收入 | 182,577,229.06 | 636,272,038.57 | 488,983,972.66 | 311,445,583.3 |
| 二、营业总成本 | 157,841,477.13 | 573,356,762.17 | 435,575,357.61 | 276,759,233.44 |
| 营业成本 | 31,988,009.5 | 113,814,862.53 | 87,288,420.68 | 59,520,527.43 |
| 税金及附加 | 3,246,173.86 | 11,577,212.77 | 9,160,123.89 | 5,921,012.69 |
| 销售费用 | 98,853,901.48 | 346,645,165.12 | 276,945,987.49 | 178,846,734.9 |
| 管理费用 | 23,553,149.33 | 86,933,099.17 | 52,506,455.41 | 30,462,429.74 |
| 研发费用 | 599,923.39 | 14,670,208.35 | 9,875,884.83 | 2,236,626.52 |
| 财务费用 | -399,680.43 | -283,785.77 | -201,514.69 | -228,097.84 |
| 其中:利息费用 | 27,519.62 | 1,000,392.18 | 841,554.28 | 531,319.66 |
| 其中:利息收入 | 198,988.17 | 444,924.84 | 1,074,871.36 | 780,232.57 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 203,279.57 | 3,496,674.69 | 1,603,361.73 | 1,193,874.46 |
| 资产处置收益 | -87,487.98 | -231,318.41 | -231,318.41 | -231,283.9 |
| 资产减值损失(新) | - | -2,727,108.33 | -2,893.59 | -2,893.59 |
| 信用减值损失(新) | -431,008.17 | 1,195,607.72 | -371,267.19 | -283,632.71 |
| 其他收益 | 459,989.75 | 35,963,791.12 | 34,920,235.55 | 15,344,079.4 |
| 四、营业利润 | 24,880,525.1 | 100,612,923.19 | 89,326,733.14 | 50,706,493.52 |
| 加:营业外收入 | 34,504.22 | 15,168,743.49 | 14,797,108.88 | 222,701.56 |
| 减:营业外支出 | 6,522.48 | 2,111,159.25 | 1,905,556.09 | 1,764,589.53 |
| 五、利润总额 | 24,908,506.84 | 113,670,507.43 | 102,218,285.93 | 49,164,605.55 |
| 减:所得税费用 | 5,260,136.43 | 20,546,373.98 | 20,455,014.49 | 11,425,475.91 |
| 六、净利润 | 19,648,370.41 | 93,124,133.45 | 81,763,271.44 | 37,739,129.64 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 19,648,370.41 | 93,124,133.45 | 81,763,271.44 | 37,739,129.64 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 19,648,370.41 | 92,580,749 | 81,763,271.44 | 37,557,144.18 |
| 少数股东损益 | - | 543,384.45 | - | 181,985.46 |
| 扣除非经常损益后的净利润 | 19,276,554.51 | 48,989,988.94 | 39,947,274.74 | 25,022,156.54 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.11 | 0.5 | 0.44 | 0.2 |
| (二)稀释每股收益 | 0.11 | 0.5 | 0.44 | 0.2 |
| 八、其他综合收益 | -653,642.24 | -1,071,743.36 | -561,524.46 | -207,233.14 |
| 归属于母公司股东的其他综合收益 | -653,642.24 | -1,071,743.36 | -561,524.46 | -207,233.14 |
| 九、综合收益总额 | 18,994,728.17 | 92,052,390.09 | 81,201,746.98 | 37,531,896.5 |
| 归属于母公司股东的综合收益总额 | 18,994,728.17 | 91,509,005.64 | 81,201,746.98 | 37,349,911.04 |
| 归属于少数股东的综合收益总额 | - | 543,384.45 | - | 181,985.46 |
| 公告日期 | 2026-04-28 | 2026-04-28 | 2025-10-29 | 2025-08-15 |
| 审计意见(境内) | | 标准无保留意见 | | |